Israel COVID-19 study finds South Africa variant able to ‘break through’ Pfizer vaccine

A new study from Israel indicates the South Africa variant of the coronavirus can “break through” the Pfizer/BioNTech vaccine to some degree. A team from Tel Aviv University and Clalit Health Services found that the prevalence of the South Africa variant among patients who received both doses of the vaccine was around eight times higher than those unvaccinated – 5.4% versus 0.7%. The study compared over 400 people who received at least one shot of the vaccine and contracted the coronavirus with the same number who were infected and unvaccinated. “We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group,” said Tel Aviv University’s Adi Stern. “This means that the South African variant is able, to some extent, to break through the vaccine’s protection.”